Valpromide, > = 97 %(NMR)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Valpromide has been used to pretreat NIH/3T3 cells to test its effect on cytomegalovirus (CMV) viral replication. It has also been used to test its antiviral functionality in herpes simplex virus type 1 (HSV-1) infected human oligodendroglioma (HOG) cells. It may be used to test its effect on apoptosis induction in astrocytes.

Biochem/physiol Actions

Valpromide possesses antipsychotic property. It lacks the toxic and teratogenic effects of valproicacid. It also lacks the histone deacetylase (HDAC) inhibitory activity of valproic acid.

Valpromide (VPD) is a derivative of valproic acid (VPA) and is used as an antiepileptic drug. It is hydrolyzed quickly to VPA in vivo, but has intrinsic anticonvulsant activity.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

10, 50 mg in glass bottle